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There is an emerging consensus that when investigators obtain genomic data from research participants, they may incur an
ethical responsibility to inform at-risk individuals about clinically significant variants discovered during the course of their
research. With whole-exome sequencing becoming commonplace and the falling costs of full-genome sequencing, there will
be an increasingly large number of variants identified in research participants that may be of sufficient clinical relevance to
share. An explicit approach to triaging and communicating these results has yet to be developed, and even the magnitude of
the task is uncertain. To develop an estimate of the number of variants that might qualify for disclosure, we apply recently
published recommendations for the return of results to a defined and representative set of variants and then extrapolate
these estimates to genome scale. We find that the total number of variants meeting the threshold for recommended dis-
closure ranges from 3955–12,579 (3.79%–12.06%, 95%CI) in the most conservative estimate to 6998–17,189 (6.69%–16.48%,
95% CI) in an estimate including variants with variable disease expressivity. Additionally, if the growth rate from the
previous 4 yr continues, we estimate that the total number of disease-associated variants will grow 37% over the next 4 yr.
[Supplemental material is available for this article.]
In genomics, there is an emerging consensus that when investi-
gators obtain genetic data from research participants, they may
incur an ethical responsibility to inform at-risk individuals about
clinically significant variations discovered during the course of their
research (Bookman et al. 2006; Wolf et al. 2008a,b; Fabsitz et al.
2010). Perhaps the largest obstacle to reviewing and communi-
cating incidental findings in genomics research is the sheer mag-
nitude of the task. When performing whole-genome sequencing,
we expect to observe hundreds of variants in each individual par-
ticipant from the over 100,000 variants that have been previously
associated with disease (Ashley et al. 2010). The proportion of
these that would meet criteria for disclosure has not previously
been considered.
Because of the complexities inherent in exposing participants
to predictive genetic information discovered outside of the clin-
ical context (Kohane et al. 2006; Meltzer 2006; Wolf et al. 2008a;
Johnson et al. 2010) and because of concerns about blurring the
lines between research and clinical care (Caulfield et al. 2008),
there has been extensive debate about whether it is appropriate to
communicate results derived from genetic research to study par-
ticipants (Fernandez et al. 2003; Bookman et al. 2006; Fernandez
and Weijer 2006; MacNeil and Fernandez 2006; Meltzer 2006;
Kozanczyn et al. 2007;Wolf et al. 2008a,b; Fabsitz et al. 2010). Several
bodies have presented recommendations for the return of individual
genetic results to participants, including the National Bioethics
Advisory Commission (NBAC), the Centers for Disease Control and
Prevention (CDC), the National Cancer Institute (NCI), and the
National Heart, Lung, and Blood Institute (NHLBI) (Table 1; Beskow
et al. 2001; White and Gamm 2002; Bookman et al. 2006; Teutsch
et al. 2009; Fabsitz et al. 2010; http://biospecimens.cancer.gov/
resources/publications/workshop/rrra.asp). Although these recom-
mendations vary, they all recognize an obligation to return at least
some research findings. While there is no set of universally accepted
standards for disclosure, there is some similarity among their criteria
for returning individual research results to participants. Each of these
groups places priority on the scientific validity of the reported asso-
ciation, the clinical significance of the associatedphenotype, and the
availability of beneficial medical interventions.
In support of translational medicine, hundreds of thousands
of participants have provided samples to research biorepositories
(Kohane et al. 2007; McGuire 2008; Roden et al. 2008; Blow 2009).
Inevitably, analyses of these samples will identify both novel and
previously discovered variants that confer disease risk. Consider-
ing that there are already over 100,000 genetic variants cited in the
medical literature (Hindorff et al. 2011), how many of these vari-
ants will meet an ethical obligation for disclosure to participants?
To answer this question,we estimated theproportion of known
genomic variants that would meet the expectation to report to
participants based on published guidelines, using the most recently
published recommendations (Fabsitz et al. 2010) as amodel. These
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recommendations were selected because they incorporate most of
the commonly articulated criteria. TheNHLBI 2010working group
concluded that individual genetic results should (with conditions)
be offered to study participants in a timely manner if they meet all
of the following criteria (recommendation 1):
1. The genetic finding has important health implications for the par-
ticipant and the associated risks are established and substantial.
2. The genetic finding is actionable; that is, there are established
therapeutic or preventive interventions or other available actions
that have the potential to change the clinical course of the disease.
3. The test is analytically valid and complies with all applicable laws.
4. During the informed consent process or subsequently, the study
participanthas opted to receive his/her individual genetic results.
We selected a representative sample of disease-associated
genetic variants from the scientific literature and reviewed each
variant to assess the characteristics that would help determine
whether investigators would be expected to report it according to
these 2010 recommendations. We then extrapolated these results
to the genome scale, estimating the total number of variants that
would satisfy these disclosure criteria.
Results
An expert committee of three certified genetic counselors reviewed
and scored a representative sample of 160 disease-associated vari-
ants thatwere randomly sampled fromdatabases that curate genetic
findings from the scientific literature. Each variant was scored on
multiple characteristics, including the validity of its disease asso-
ciation, the severity of the associated disease with and without
treatment, and the potential to improve medical outcome with in-
tervention. We then applied disclosure criteria from the 2010 guide-
lines (Fabsitz et al. 2010) to the sample under the strictest possible
interpretation and then again with an interpretation that allowed
for greater variability of disease expression. Finally, we extrapolated
these results to the genome scale, estimating the total number of
variants that would satisfy these disclosure criteria (Table 2).
Under the strictest interpretation, which required possible
expression of severe disease, we identified that 6.9% of the variants
reviewed would meet criteria for disclosure to research partici-
pants. An additional 3.8%of all sampled variants is associatedwith
variable disease expression or uncertain risk for severe disease and
would meet the criteria for disclosure if disease expression were at
Table 1. Summary of key U.S. guidelines on the return of genetic research results
Disclosure policy
To whom information
can be disclosed
National Bioethics Advisory
Commission, 1999
Individual data only if valid, confirmed,
have significant health implications,
can treat or ameliorate
Research participant
Centers for Disease Control
and Prevention, 2001
Aggregate and individual data only if
likely to lead to evidence-based
intervention
Research participant
RAND Corp., 2003 Aggregate data only Public: via internet, newsletter,
scientific meeting
National Heart, Lung, and
Blood Institute (NHLBI), 2004
Individual data only if analytically valid,
replicable, and significant; have severe
health implications; can treat or prevent
Research participant
National Cancer Institute (NCI), 2007 Aggregate and individual data Research participant, participant’s
health care provider, family
Public Responsibility in Medicine
and Research, 2007
Individual data only if compelling rationale Research participanta
National Institutes of Health
Genome-Wide Association
Studies, 2007
Individual data only in rare circumstances Downstream users disclose to
contributing investigator
National Human Genome Research
Institute, 2008
Right to access individual data unless results
are of unproven clinical validity and
judged by IRB to be of no benefit to subjects
Research participant
NHLBI, 2010 Individual data only if analytically valid,
replicable, and significant, have important
health implications, can treat or prevent
Research participant
NCI, 2011 Aggregate and individual data if research
participant has consented to receive research
results and if results are analytically valid,
clinically significant or serious, and clinically
actionable
Research participant
While there is no universally accepted set of standards for the return of genetic research results, many of the groups that have visited this issue have placed
priority on the scientific validity, clinical significance, and availability of medical interventions. This is a representative list of U.S. guidelines. It is not intended
to be exhaustive.
aResearch participant must be informed about plans to disclose so investigator can disclose to others with participant consent.
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least ‘‘severe’’ in some cases. With these additional variants in-
cluded, 10.6% meets the criteria for disclosure.
Among the 104,304 disease-associated variants genome-wide
from the published research considered in our study (a sample of
160 randomly sampled from curated pathogenic variant databases:
Human Gene Mutation Database (HGMD), Online Mendelian
Inheritance in Man (OMIM), and National Human Genome Re-
search Institute (NHGRI) Catalog of Genome-Wide Association
Studies (GWAS) (Amberger et al. 2009; Stenson et al. 2009; Hindorff
et al. 2011), we conservatively estimate that investigators could be
urged to share 7171 [3955–12,579, 95%CI] of those variants with
participants. If variants with variable disease expression are in-
cluded (which meet all other required criteria and also may result
in severe disease,) then 11,082 [6998–17,189, 95%CI] variants
would be shared, genome-wide (Table 3).
We further project an increase in the number of disease-
associated variants that will be identified in publications. By using
4 yr of historical disease-associated variant data from HGMD and
the NHGRI Catalog of Published GWAS (98% of our variant data
set) at a quarter-year resolution, we identified an average growth
rate of 10,437 variants per annum (R2 = 0.9977) in a conservative
linear growth scenario and increasing growth rates in more ag-
gressive scenarios (Fig. 1).
It is expected that by 2015, there will be over 150,000 pub-
lished disease-associated variants using a conservative linear esti-
mate andover 190,000 if extrapolating using an exponential growth
model. Estimates are presented for growth in the number of variants
that would meet the recommendation to share with participants if
a conservative, steady growth (linear model, R2 = 0.9976) is selected
(Table 4), when extrapolating the observed 10.6% variant disclosure
rate from our sample using Fabsitz et al. (2010) recommendation 1.
Additionally, to evaluate the number of variants we might
encounter in research subjects, we analyzed 36 whole-genome
sequences of asymptomatic individuals that were publicly avail-
able from Complete Genomics (Drmanac et al. 2010; http://www.
completegenomics.com/sequence-data/download-data/). We iden-
tified that each of these samples carried an average of 2120 sub-
stitution variants from our study knowledge base (Table 5). This
demonstrates that a substantial number of previously identified
variants are likely to be observed in the whole-genome sequence
analysis of asymptomatic individuals, although it is not yet pos-
sible to accurately estimate the actual number of these variants
that will be reportable to each individual.
Discussion
This is the first study to estimate the number of published disease-
associated variants that met the criteria for disclosure to research
participants, according to the recommendations of a recent con-
sensus group (Fabsitz et al. 2010). Extrapolating to genome scale,
investigators following these guidelines may be responsible for
disclosing over 11,000 variants today and over 16,000 variants by
the year 2015.
The return of incidental research findings has been the sub-
ject of debate for many years. Still contentious and unresolved, for
example, is the optimal approach to disclosing suspicious inci-
dental findings to subjects of neuroimaging studies (Illes et al.
2004, 2010; Palmour et al. 2011). Finding a lesionon the computed
tomography scan of an asymptomatic research subject creates a
complex dilemma; the meaning of the lesion may be unclear when
the prior probability of disease is low (Sadatsafavi et al. 2010; http://
bioethics.gov/cms/meeting-four-agenda). In genomics, the core eth-
ical issues are similar, but the informationmanagement task becomes
daunting at the genome scale.
Without new tools for investigators and institutions, emerg-
ing requirements for the return of results in genomicsmay become
rapidly unmanageable in the setting of a growing corpus of known
disease-associated variants. The scientific review process to mea-
sure the validity and communicability criteria for each of these
variants would be protracted, and even once the estimated 11,000–
16,000 qualified variants are identified, there is the process of
evaluating and prioritizing those identified in each participant.
Table 2. Applying return of results recommendations to our set of genetic variant annotations
National Heart, Lung, and Blood Institute (NHLBI) 2010 recommendation 1 as applied to our variant annotations
Constraint Criterion Value (ranges from low to high, left to right)
All must be met Validity of association Low Moderate High
Phenotypic severity 1 2 3 4 5
Improves with treatment 0 1 2 3 4
Analytic validity and laws We assume legal testing in a Clinical Laboratory Improvement Amendment–approved laboratory
Participant consent We assume that the participant has consented
Each variant in this study was reviewed and annotated by an expert committee of three genetic counselors and was given a score for each of the criteria
cited in the National Heart, Lung, and Blood Institute (NHLBI) 2010 recommendations. If each of the values for the variant met the recommendations (in
the zone highlighted in gray in each row), then that variant was judged to have met all criteria to warrant disclosure. If the score for even one criterion is in
a zone in white, there is no responsibility to disclose the variant to a participant.
Table 3. The number of variants from our sample that would be shared with participants according to National Heart, Lung, and Blood
Institute (NHLBI) 2010
Variant sample
Ethical obligation to
disclose the variant
Variant may be disclosed
(variable disease expression)
No ethical obligation
to disclose variant
Unknown or
insufficient information
NHLBI 2010 sample 11 (6.88%) [3.80–12.06] 6 (3.75%) [1.58–8.17] 140 (87.50%) [81.37–91.80] 3 (1.88%) [0.42–5.68]
NHLBI 2010 genome-wide 7171 [3955–12,581] 3911 [1649–8526] 91,266 [84,871–95,753] 1956 [435–5925]
Recommendation 1 is shown in the upper row. The lower row shows an extrapolation from the sample to the whole genome. Cells include the number of
results to be communicated in each category, the associated percentage of disease-associated variants, and 95% confidence intervals.
Researchers may tell subjects about many variants
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This is a drastically larger burden on investigators than the review
of a single neuroimaging study per participant—the impact on
genomics research could be quite serious. Are we setting the stage
for participants to be disappointed and for researchers to become
legally liable for something they cannot realistically accomplish?
While published policy recommendations are certainly well
intentioned, they are difficult to apply when such a large number
of potential variants are worthy of communication to participants.
We need more realistic standards that balance the ethical arguments
in favor of disclosing results with the reality of what is feasible to
review and communicate. Investigators and leaders of biorepositories
will not be able to meet this potential ethical responsibility without
substantial, evolving knowledge bases and enhanced processes. Ad-
ditional questions from the current guidelines remain: Is CLIA certi-
fication really equivalent to analytic validity?What is the appropriate
predictive risk cutoff for having clinical significance or ‘‘important
health implications’’? Does a GWAS-identified allele that increases
relative risk for a rare disease by 10% warrant communication to
participants?
Our estimates are based on an ambitious approach of inves-
tigating previously identified disease-associated variants that have
been described in the scientific literature. To execute returnof results
at this level, researchers and research subjects would necessarily rely
on yet-to-be developed tools for identifying and presenting variants
of importance across the genome. In themeantime, as these genome-
scale decision and risk tools are developed, there are simple ap-
proaches to reduce the burden inherent in analyzing incidental
findings in the clinical interpretation of whole-genome sequences.
One is to limit reportable findings to those actually discovered
during the normal course of research, likely including only a small
set of genes. Alternatively, when the scope of the primary research
is genome-wide, it may be more appropriate to ask investigators to
check for a panel of well-known variants thatmeet a high standard
of clinical significance and actionability, throughout the genome.
Unfortunately, no such list yet exists.
The National Institutes of Health (NIH) is calling for empirically
informed guidelines for the return of results (http://grants1.nih.
gov/grants/guide/rfa-files/RFA-HG-10-017.html; http://grants1.nih.
gov/grants/guide/rfa-files/RFA-HG-11-003.html; http://grants1.
nih.gov/grants/guide/rfa-files/RFA-HG-11-004.html), in parallel,
there should be support for new communication strategies and
dynamic data sources to support this disclosure.While there are data
sources emerging that measure the clinical and syntactic validity of
previously identified variants (Khoury et al. 2009; http://evidence.
personalgenomes.org/guide_impact_score; Tong et al. 2011), there
is presently no knowledge base that includes the necessary infor-
mation to reach disclosure decisions.Oneway to prospectively build
such a database would be to create an obligation for investigators to
report the novel variant associations identified in research studies.
However, many investigators are not necessarily qualified to create
clinical annotations that assess risk/benefit tradeoffs and other
reportability criteria.
Further, how will the participant’s clinical context (Beskow
and Burke 2010) and preferences be taken into account? As the
science and practice of full-genome interpretation matures (Ashley
et al. 2010; Ormond et al. 2010), the next challenge becomes per-
sonalization of the communication strategy for very large numbers
of variants, considering risks and benefits for each individual
(Fabsitz et al. 2010; Kohane and Taylor 2010) that include the clin-
ical validity and utility of each variant (Holtzman et al. 1997).
While the disclosure of a small number of individual genetic risk
variables has been measured in empirical trials (Green et al. 2009;
Teutsch et al. 2009), these approaches are limited because of the
sheer volume of variants that are and will become available, along
with the changing nature of both the variant information and the
therapeutic considerations that impact clinical utility. Although
there is mounting evidence that participants are eager to receive a
Figure 1. Estimated growth of the knowledge base of disease-associ-
ated variants and the number of variants that may meet the threshold for
recommended communication to research participants. The quarterly
totals of variants from the Human Gene Mutation Database and the Na-
tional Human Genome Research Institute (NHGRI) Catalog of Published
Genome-Wide Association Studies (GWAS) over 4 yr were the basis for
creating logarithmic (lower line) and exponential (upper line) regressions
(R2 = 0.9976, 0.9972). The range of likely growth is highlighted in blue
between these two lines. These regressions were extrapolated to estimate
the possible growth rates of disease-associated genetic variants in the
following 4 yr. Linear growth rate data (R2 = 0.9977) were also used to
extrapolate the estimated number of variants that would be shared with
research participants under the 2010 guidelines for disclosure. Bars, 95%
confidence intervals for each quarterly estimate.
Table 4. Estimated growth of disease-associated variants and the
estimated growth of disease-associated variants that would meet
the threshold for recommended disclosure over the next 4 yr
Date
Expected total
known variants
Expected NHLBI 2010 potentially
communicated variants
[95% confidence intervals]
Mar-06 59,666 6,339 [3,989, 9,835]
Mar-07 69,851 7,421 [4,670, 11,514]
Mar-08 79,651 8,462 [5,326, 13,129]
Mar-09 89,352 9,493 [5,974, 14,728]
Mar-10 101,686 10,804 [6,799, 16,761]
Mar-11 110,708 11,762 [7,403, 18,248]
Mar-12 121,091 12,865 [8,097, 19,960]
Mar-13 131,447 13,966 [8,789, 21,667]
Mar-14 141,803 15,066 [9,482, 23,374]
Mar-15 152,159 16,166 [10,174, 25,081]
We used data from two major sources of disease-associated variants (the
Human Gene Mutation Database and the National Human Genome Re-
search Institute Genome-Wide Association Studies Catalog) over the
previous 4 yr to estimate the growth of disease-associated variants and the
number of those variants that would meet the threshold for disclosure to
research participants. These estimates are based on the observed 10.6%
variant disclosure rate from our sample when following National Heart,
Lung, and Blood Institute (NHLBI) recommendation 1. In brackets are the
95% confidence intervals for NHLBI disclosure estimates.
Cassa et al.
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broad range of genetic risk information upon contribution of ma-
terials and data to biorepository researchers (Murphy et al. 2008,
2009), many institutions have not recorded participant disclosure
preferences. We have not explored such preferences in this study
but, rather, started with the assumption that participants have
consented to receive all possible results.
When there are results that participants have requested that
meet the ethical criteria for disclosure, there is not yet a consensus
on the proper mechanism for participant notification. There will
be challenges in coordinating and funding this careful commu-
nicationwith research subjects, asmany pure-science investigators
do not have ready access to genetic counseling staff or other cli-
nicians, and there is no broadly established mechanism for fund-
ing support for these endeavors.
There are several limitations to this study. The variant sample
size is small in comparison to the number of known variants.
While this creates broad confidence intervals, we are able to pro-
duce estimates that inform feasibility of the overall task. Also, in
order to create a genome-wide estimate, our sampling strategy was
inclusive of all possible variants in the knowledge bases we con-
sidered, rather than sampling the most frequently occurring vari-
ants. While these variants have been previously associated with
disease in the scientific literature, they largely have been derived
from small disease cohorts with limited control populations such
that a reassessment of the evidence for pathogenicity is required.
This process involves manual review of the evidence for each
variant; however, we anticipate that a reasonable subset of variants
will be filtered out as likely benign based upon the expanded fre-
quency data that are emerging from whole-genome studies.
Additionally, for asymptomatic individuals, there is currently
no authoritative source for relative risk of disease for the majority
of variants in the knowledge bases we used; most manuscripts re-
view a disease in the context of a small number of individuals, so
there may be limitations to external generalizability that will be
uncovered as new whole-genome data become available. When
such data are reliably available, future studies should evaluate
these estimates in the context of the likelihood of encountering
each variant in participants. Additionally, there is no established
quantitative standard in these published guidelines about what
constitutes an ‘‘established and substantial’’ associated risk for
disease. For this study, we relied on a human review process that
was necessarily subjective, although we used a consensus-based
process that reviewed a primary associated publication and clinical
research data sources to increase objectivity. These reviews were
conducted for research purposes, outside of the clinical context of
specific patients, which presents limitations for robustness and
external generalizability. The growth estimates are also based on
the assumption that the pace of discovery will continue at current
rates for the coming four years, however this rate of discovery may
change over time.
Our findings have implications not only for genome re-
searchers but also for clinicians. Microarrays and targeted se-
quencing are already used diagnostically, and it is anticipated that
whole-genome sequencing will eventually be integrated into
clinical care (Green and Guyer 2011). While suspicious lesions
discovered during imaging research are routinely investigated
clinically, our findings suggest that the same standard will not be
feasible in genomic medicine. Issues to address in future research
include diagnostic and intervention costs (both at present and
downstream) and the decision support systems for prioritizing and
communicating large numbers of variants, in conjunction with
family history and/or clinical presentation.
Methods
Sources of disease-associated variant data and creation
of a study sample
The set of variants for clinical annotation and review were ran-
domly sampled, using a stratifiedmethodology, fromhigh-quality,
curated databases (Table 6) that include a variety of variant types,
including rare mutations, large insertions and deletions, rear-
rangements, and polymorphisms. These include the HGMD
(Stenson et al. 2009), the NHGRI Catalog of Published GWAS
(Hindorff et al. 2001) and the OMIM (Amberger et al. 2009).When
variants were listed in more than one repository, duplicate entries
were removed.
All variant records in the HGMD and NHGRI databases
include an associated reference publication or locus-specific data-
base (LSDB) entry that reports an associationwith a phenotype. All
OMIM records have a corresponding OMIM entry, and many also
have a reference publication.
We adopted a stratified sampling strategy to select a repre-
sentative subset of variants that was drawn proportionally from
each data source (Table 6). Each data source and variant category
were evaluated separately (withinHGMD, there are 10 variant types
we consider in Table 6), and we substratified the sample among the
subcategories in proportion to their frequencies. We first calculated
the proportion of each variant type with respect to the entire set of
variants we considered (104,304 total variants). We thenmultiplied
that subset percentage by 160 and took the integer portion of that
decimal number plus a simulated coin flip multiplied by the re-
maining (nondecimal) portion of thenumber to determinewhether
an extra variant would be sampled for that category. This resulted in
an integer number of variants to review for each category. Though
the large majority of variants are derived from HGMD, we propor-
tionally sampled from all three databases.
To calculate the order of review for variants within each cat-
egory, we assigned a randomly generated, unique number to each
variant. The sampling strategy then rank-ordered each variant by
its random number and included the determined number of var-
iants from that category into the final variant sample.
Exclusion criteria
To avoid a bias toward selecting higher-quality studies, we evalu-
ated and independently annotated as many of the sampled vari-
ants as possible. Two of 160 sampled variants were not analyzed
Table 5. Aggregate results from the whole-genome
interpretation of 36 Complete Genomics genomes of asymptomatic
individuals
Total study
variants
identified
Homozygous
study
variants
Heterozygous
study
variants
Minimum 1812 623 1028
Maximum 2252 835 1371
Average 2120 737 1214
Standard deviation 70 54 74
Whole-genome sequence data from 36 publicly available genomes
of asymptomatic individuals (Drmanac et al. 2010; http://www.
completegenomics.com/sequence-data/download-data/) were analyzed,
using the substitution variants from the knowledge base in this study. The
total number of variants identified in each sequence is reported, along with
the subset of those that are homozygous and heterozygous.
Researchers may tell subjects about many variants
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because the primary reference articles were not available in En-
glish, and another was excluded because there was no reference
available. Excluded variants, where we were unable to create clin-
ical annotations, were categorized as ‘‘unknown.’’
Creating scores for each of the NHLBI 2010
recommendation criteria
For each variant in the study sample, we created scores for the key
factors cited in the NHLBI 2010 recommendations. We combined
the areas of clinical review fromNHLBI 2010 into threemajor axes:
clinical impact of phenotype, clinical actionability, and associa-
tion validity (Table 7).
Clinical impact of phenotype focuses on phenotype-specific
characteristics, including reproductive impact and age of onset.
Clinical actionability focuses on available medical interventions
and preventative behaviors that may be applied, given knowledge
of the phenotypic risk, including the efficacy of available inter-
ventions, and the impact on a patient’s life whenundergoing those
interventions. The association validity focuses on the strength and
validity of the reported genotype-phenotype associations, including
a relative risk value (when available) and a scaled validity score.
Within each category or subcategory, we allowed for a range
of scores, most often using a five-point rating scale (Supplemental
Materials S1). Finally, we created written guidance to consistently
categorize the scores for each clinical annotation component. We
categorized the validity of the association as low,moderate, or high
and supplemented that with an explanatory comment field that
addressed the type of mutation, existence of consistent functional
studies, and familial segregation, among other factors.
To generate consensus scores for each category, three certified
genetic counselors reviewed supporting data from both clinical
and research resources (including GeneReviews [Pagon 2006], OMIM
[Amberger et al. 2009], and eMedicine [Q MRS 2002], among
others) to contextualize the phenotype, determine the strength of
the association between the variant and the disease, and identify
any potential treatments. Additionally, we thoroughly reviewed
the primary citation associated with each variant in the knowledge
bases. Notably, each validity score is based only on the above data, an
approachmotivated by the significant time
and resources that would be required to
conduct an exhaustive literature review for
a sample set of this size. Therefore, the
validity scores are based on careful consid-
eration of the presented data but are not
derived fromany specific algorithmandare
categorized broadly as low, moderate, or
high validity.
The genetic counselors clinically
annotated each variant association, and
when all three counselors were in agree-
ment, the score was considered a final
consensus score. Upon review of the avail-
able information, the genetic counselors
were able to reach consensus in almost all
but one case. However, where there was
not a true consensus, the score was de-
termined by the majority opinion, with
two of the three counselors in agreement.
Occasionally, a specific characteris-
tic in a variant annotation was not scor-
able; some examples include a highly
variable disease severity or age of onset,
whichwewouldmark as ‘‘variable’’ with a
comment, or if insufficient information
was available to reach a score, the characteristic was scored as
‘‘unknown.’’ We marked items as ‘‘not applicable’’ when the score
was not applicable to a specific variant or phenotype.
Evaluating the responsibility
for communication to a participant
Once the representative sample of variants was clinically annotated,
we evaluated whether each variant would be appropriate for com-
munication to research participants using communication strategies
derived from the NHLBI 2010 Working Group.
We matched each characteristic from the disclosure guidelines
to a characteristic from the clinical annotations created by the ge-
netic counselors, including strength of association, phenotypic se-
verity, and improvement with treatment. If the score for each
characteristic met the definition for the associated disclosure crite-
rion, the variant qualified for the recommendation to disclose to
participants. This is illustrated as the gray portion of Table 2. If one
or more criteria were missing or unknown, the responsibility to
disclose was designated as ‘‘ unknown.’’ If all disclosure criteria were
met but the phenotypic severity was considered variable and had
Table 6. Variant types and data sources
Data source (date of access: type
of variants included)
No. of
published
variants
No. of
sampled
variants
Percentage of
variants
in sample
HGMD (March 2010: Mutations, Insertions,
Deletions, Other)
100,329 154 96.25
HGMD missense and nonsense 56,457 86 53.75
HGMD small deletions 15,805 24 15.00
HGMD splicing 9,600 15 9.38
HGMD small insertions 6,513 10 6.25
HGMD gross deletions 6,201 10 6.25
HGMD regulatory 1,766 3 1.88
HGMD small indels 1,473 2 1.25
HGMD gross insertions 1,260 2 1.25
HGMD complex rearrangements 947 1 0.63
HGMD repeat variations 307 1 0.63
NHGRI not in HGMD (January 2010:
Genome Wide Association Study SNPs)
2,131 3 1.88
OMIM not in HGMD (June 2010:
Single Nucleotide Substitutions)
1,844 3 1.88
Total 104,304 160 100
Variants were sampled from three different databases that curate genotype-phenotype associations
derived from the scientific and medical literature. A stratified sampling method was used. HGMD in-
dicates the Human Gene Mutation Database; NHGRI, National Human Genome Research Institute; and
OMIM, Online Mendelian Inheritance in Man.
Table 7. Clinical annotation characteristics
Categories Characteristics
Clinical impact
of phenotype
Severity with treatment, severity without
treatment, age of onset,
and reproductive issues
Clinical
actionability
Efficacy of available treatment, invasiveness
and difficulty of treatment, frequency
and duration of treatment
Association validity Association validity and relative
risk (when applicable)
A team of three certified genetic counselors used a consensus-based
method to create clinical annotations for each variant in three categories:
clinical impact of phenotype, clinical actionability, and association val-
idity. For each of these categories, a set of characteristics was scored for
each variant, most often using a rating scale.
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the potential tomeet the threshold todisclose, then that variantwas
labeled ‘‘variable.’’
To focus this study on identifying the number of variants
recommended for disclosure to research participants, we excluded
a number of external factors from consideration. We specified that
all participants would have consented to learning about variants
they carried, that the genetic assay would have met analytic val-
idity standards, and that the disclosure of results to participants
was Institutional Review Board (IRB)-approved and met all state
and federal laws.
Estimating the number of variants genome-wide that met
the threshold for recommendation to communicate
under NHLBI 2010
To estimate the number of variants, genome-wide, that would meet
the threshold for recommended disclosure, we used the observed
proportion of sampled variants that fulfilled the requirements for
recommended reporting (6.88%, plus an additional 3.75%under the
less strict interpretation). To reach the estimate,weused the sampling
fraction, the proportion of the variants that we sampled from the
total variant knowledge base that was considered in this study. We
divided the number of variants that met the threshold for recom-
mended or potential communication under each disclosure strategy
by the sampling fraction to reach an estimate of variants from the
total variant knowledge base that would meet each set of criteria.
In addition to the estimate that was generated, we used the
Agresti-Coull binomial confidence interval method (Brown et al.
2001) to calculate 95% confidence intervals for each disclosure
result. Because the sample was drawn from a finite population of
variants, we completed a finite population correction factor, and
the effect was negligible because the sample size was small in
comparison to the total number of variants.
Potential growth of number of variants that would be disclosed
to participants under NHLBI 2010
We estimated the potential growth of disease-associated variants
using data from the HGMD and the NHGRI Catalog of Published
GWAS (which represented over 98% of the variants in our knowl-
edge base). We applied standard regression analysis to quarterly re-
ports of total variant counts from the previous 4 yr, calculating
logarithmic, linear, and exponential regression models, and esti-
mated the future growth of variants following a linear trend over the
following four years.
Number of previously identified substitution variants detected
in the whole-genome analysis of 36 asymptomatic individuals
We compared the whole-genome sequence data from 36 asymp-
tomatic individuals that are publicly available from Complete Ge-
nomicswith all substitutionvariants fromthe knowledgebaseused in
this study (Drmanac et al. 2010;http://www.completegenomics.com/
sequence-data/download-data/). We then calculated the maximum,
minimum, and average number of variants that were identified in
each sample, and also recorded whether each variant was hetero-
zygous or homozygous in each individual.
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